
Mahi Drugs Private Limited
Produces API for pharmaceutical industry, founded in 2012 in Vishakhapatnam, Andhra Pradesh.
Produces API for pharmaceutical industry, founded in 2012 in Vishakhapatnam, Andhra Pradesh.
Mahi Drugs Private Limited (MDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 17 December 2012 and has a history of 12 years and three months. Its registered office is in Visakhapatnam, Andhra Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 Cr and a paid-up capital of Rs 7.07 Cr.
The company currently has active open charges totaling ₹28.68 Cr. The company has closed loans amounting to ₹5.15 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sarath Pakalapati, Madhu Maganty, Venkata Talluri, and One other member serve as directors at the Company.
Visakhapatnam, Andhra Pradesh, India
+91-XXXXXXXXXX
U24233AP2012PTC084875
084875
Private Limited Indian Non-Government Company
17 Dec 2012
23 Sep 2024
31 Mar 2024
Unlisted
Roc Vijayawada
Name | Designation | Appointment Date | Status |
---|---|---|---|
Venkata Talluri ![]() | Managing Director | 25-Jul-2020 | Current |
Name | Designation | Appointment Date | Status |
---|---|---|---|
Sarath Pakalapati ![]() | Director | 09-Aug-2022 | Current |
Madhu Maganty ![]() | Nominee Director | 28-May-2022 | Current |
Veeravenkata Talluri ![]() | Director | 07-Apr-2018 | Current |
Mahi Drugs Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 9.49% increase. The company also saw a substantial fall in profitability, with a 162.41% decrease in profit. The company's net worth Soared by an impressive increase of 28.79%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
In 2023, Mahi Drugs had a promoter holding of 60.00% and a public holding of 40.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Sarath Pakalapati, Venkata Talluri and 1 more are mutual person
Sarath Pakalapati is a mutual person
Madhu Maganty is a mutual person
Madhu Maganty is a mutual person
₹28.68 Cr
₹5.15 Cr
Date | Lender | Amount | Status |
---|---|---|---|
17 Aug 2020 | Others | ₹1.92 Cr | Open |
20 Jul 2019 | Others | ₹7.50 Cr | Open |
21 Jun 2019 | Others | ₹19.26 Cr | Open |
30 Jan 2016 | Hdfc Bank Limited | ₹2.95 Cr | Satisfied |
06 Jan 2016 | Hdfc Bank Limited | ₹2.20 Cr | Satisfied |
Mahi Drugs has a workforce of 201 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Mahi Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mahi Drugs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Mahi Drugs Private Limited last Annual general meeting of members was held on 23 Sep 2024 as per latest MCA records.
Mahi Drugs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Vijayawada.
Sarath Kumar Pakalapati was appointed as a Director was appointed as a Director on 09 Aug 2022 & has been associated with this company since 2 years 8 months .
Madhu Rao Maganty was appointed as a Nominee Director was appointed as a Nominee Director on 28 May 2022 & has been associated with this company since 2 years 10 months .
A charge with Others of Rs. 1.92 Cr registered on 17 Aug 2020 with Charge ID 100359037 was modified on 12 Oct 2020.
A charge with Others amounted to Rs. 1.92 Cr with Charge ID 100359037 was registered on 17 Aug 2020.
Mahi Drugs Private Limited was incorporated on 17 Dec 2012.
The authorized share capital of Mahi Drugs Private Limited is ₹ 7.50 Cr and paid-up capital is ₹ 7.07 Cr.
Currently 4 directors are associated with Mahi Drugs Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Mahi Drugs Private Limited is Plot No.82, Jawaharlal Nehru Pharma City Parawada India, Vishakhapatnam, Andhra Pradesh, 531019.
The corporate identification number (CIN) of Mahi Drugs Private Limited is U24233AP2012PTC084875 and the company number is 084875 as per Ministry of Corporate Affairs (MCA).
According to the financial reports for the fiscal year 2023, the revenue trend for Mahi Drugs Private Limited has risen by 9.49%.
As Per 2023 financial reports, 201 employees are currently employed by Mahi Drugs Private Limited.
The financial reports for the fiscal year 2023 indicates that The net worth of Mahi Drugs Private Limited has experienced an upsurge of 28.79%.
As per the financial statements for fiscal Year 2023, The total open charges for Mahi Drugs Private Limited amount to ₹ 28.68 Cr.
The most recent Balance Sheet for Mahi Drugs Private Limited was filed with the ROC on 31 Mar 2024.
Search company & director profiles for free and gain access to critical business data.
RP
BM
VK
RN
RN
OV
KK
VG